JP2019513829A - 抗炎症剤、抗転移剤及び／又は抗癌剤として使用するためのアミノ安息香酸誘導体 - Google Patents

抗炎症剤、抗転移剤及び／又は抗癌剤として使用するためのアミノ安息香酸誘導体 Download PDF

Info

Publication number
JP2019513829A
JP2019513829A JP2019503603A JP2019503603A JP2019513829A JP 2019513829 A JP2019513829 A JP 2019513829A JP 2019503603 A JP2019503603 A JP 2019503603A JP 2019503603 A JP2019503603 A JP 2019503603A JP 2019513829 A JP2019513829 A JP 2019513829A
Authority
JP
Japan
Prior art keywords
cancer
compound
acetyl
substituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
JP2019503603A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019513829A5 (enExample
Inventor
ベルベ、ジェルヴェ
− モレノ、カルロス レイエ
− モレノ、カルロス レイエ
Original Assignee
３アール ヴァロ、エス．イー．シー．
３アール ヴァロ、エス．イー．シー．
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by ３アール ヴァロ、エス．イー．シー．, ３アール ヴァロ、エス．イー．シー． filed Critical ３アール ヴァロ、エス．イー．シー．
Publication of JP2019513829A publication Critical patent/JP2019513829A/ja
Publication of JP2019513829A5 publication Critical patent/JP2019513829A5/ja
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/448—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide
    • C07D207/452—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. maleimide with hydrocarbon radicals, substituted by hetero atoms, directly attached to the ring nitrogen atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/30—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members
    • C07D207/34—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having two double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/36—Oxygen or sulfur atoms
    • C07D207/40—2,5-Pyrrolidine-diones
    • C07D207/404—2,5-Pyrrolidine-diones with only hydrogen atoms or radicals containing only hydrogen and carbon atoms directly attached to other ring carbon atoms, e.g. succinimide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/44—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members
    • C07D207/444—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5
    • C07D207/456—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having three double bonds between ring members or between ring members and non-ring members having two doubly-bound oxygen atoms directly attached in positions 2 and 5 with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to other ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Indole Compounds (AREA)
JP2019503603A 2016-04-11 2017-04-10 抗炎症剤、抗転移剤及び／又は抗癌剤として使用するためのアミノ安息香酸誘導体 Ceased JP2019513829A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662320654P 2016-04-11 2016-04-11
US62/320,654 2016-04-11
PCT/CA2017/050432 WO2017177316A1 (en) 2016-04-11 2017-04-10 Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents

Publications (2)

Publication Number Publication Date
JP2019513829A true JP2019513829A (ja) 2019-05-30
JP2019513829A5 JP2019513829A5 (enExample) 2020-05-21

Family

ID=60041299

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019503603A Ceased JP2019513829A (ja) 2016-04-11 2017-04-10 抗炎症剤、抗転移剤及び／又は抗癌剤として使用するためのアミノ安息香酸誘導体

Country Status (6)

Country Link
US (2) US10759754B2 (enExample)
EP (1) EP3442943B1 (enExample)
JP (1) JP2019513829A (enExample)
CN (1) CN109071433A (enExample)
CA (1) CA3020348A1 (enExample)
WO (1) WO2017177316A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10787701B2 (en) 2010-04-05 2020-09-29 Prognosys Biosciences, Inc. Spatially encoded biological assays
EP4234716A3 (en) 2013-06-25 2023-12-06 Prognosys Biosciences, Inc. Methods for determining spatial patterns of biological targets in a sample
CU24661B1 (es) 2018-01-17 2023-05-11 Aurigene Discovery Tech Ltd Compuestos de alquinileno sustituidos como agentes anticancerígenos
CA3021417A1 (en) * 2018-10-18 2020-04-18 3R Valo, S.E.C. Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
CN114516819B (zh) * 2022-02-25 2024-02-27 顺毅宜昌化工有限公司 一种n,n’-二乙酰基肼的制备方法
CN117447353A (zh) * 2023-09-21 2024-01-26 爱斯特（成都）生物制药股份有限公司 一种氘可来昔替尼中间体的制备方法

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091246A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3046301A (en) 1959-10-29 1962-07-24 Burroughs Wellcome Co Method of making chlorambucil
EP3954394A1 (en) * 2015-06-19 2022-02-16 Centurion BioPharma Corporation Delivery systems for controlled drug release

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006091246A1 (en) * 2004-11-01 2006-08-31 University Of Southern California Novel compounds for treatment of cancer and disorders associated with angiogenesis function

Non-Patent Citations (7)

* Cited by examiner, † Cited by third party
Title
AL-AZZAWI, AM ET AL.: "SYNTHESIS AND ANTIMICROBIAL ACTIVITY OF NEW SUCCINIMIDES BEARING DIFFERENT HETEROCYCLES", INTERNATIONAL JOURNAL OF RESEARCH IN PHARMACY AND CHEMISTRY, vol. 4, JPN6021012994, 2014, pages 755 - 762, XP002756060, ISSN: 0004482933 *
BEYER, U ET AL.: "Synthesis of new bifunctional maleimide compounds for the preparation of chemoimmunoconjugates", MONATSHEFTE FUER CHEMIE, vol. 128, JPN6021012997, 1997, pages 91 - 102, XP009023613, ISSN: 0004482931, DOI: 10.1007/BF00807643 *
DESAI, GT ET AL.: "Study of novel pyrrolidine compounds", JOURNAL OF CHEMICAL AND PHARMACEUTICAL RESEARCH, vol. 6, JPN6021012992, 2014, pages 2624 - 2627, XP009509567, ISSN: 0004482934 *
FAHMY, MM ET AL.: "Novel Antimicrobial Organic Thermal Stabilizer and Co-Stabilizer for Rigid PVC", MOLECULES, vol. 17, JPN6021012991, 2012, pages 7927 - 7940, XP055526069, ISSN: 0004482935, DOI: 10.3390/molecules17077927 *
HAMELIN-MORRISSETTE, J ET AL.: "Identification of an anti-inflammatory derivative with anti-cancer potential: The impact of each of", EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY, vol. 96, JPN6021012996, 2015, pages 259 - 268, XP029168227, ISSN: 0004482932, DOI: 10.1016/j.ejmech.2015.04.026 *
HIRAN, BL ET AL.: "Radical Copolymerization of Maleimide Derivatives with n-butyl Acrylate and Characterization of Poly", INTERNATIONAL JOURNAL OF POLYMERIC MATERIALS AND POLYMERIC BIOMATERIALS, vol. 62, JPN6021012988, 2013, pages 243 - 246, ISSN: 0004482937 *
MOSTAFAVI, SH ET AL.: "Optimization of paclitaxel-loaded poly (D,L-lactide-co-glycolide-N-p-maleimido benzoic hydrazide) na", PARHACEUTICAL DEVELOPMENT AND TECHNOLOGY, vol. 20, JPN6021012989, 2015, pages 845 - 853, ISSN: 0004482936 *

Also Published As

Publication number Publication date
CN109071433A (zh) 2018-12-21
EP3442943A4 (en) 2019-03-20
EP3442943A1 (en) 2019-02-20
US10759754B2 (en) 2020-09-01
EP3442943B1 (en) 2020-10-07
US20190127325A1 (en) 2019-05-02
US20210002222A1 (en) 2021-01-07
WO2017177316A1 (en) 2017-10-19
CA3020348A1 (en) 2017-10-19

Similar Documents

Publication Publication Date Title
JP2019513829A (ja) 抗炎症剤、抗転移剤及び／又は抗癌剤として使用するためのアミノ安息香酸誘導体
JP6162133B2 (ja) 潰瘍性大腸炎を抑制するプロトベルベリン生物学的アルカロイド誘導体およびその使用
US12448372B2 (en) Class of triaromatic compounds targeting bifunctional phosphorylation site of STAT3 and applications thereof
JP2003515590A5 (enExample)
US10808005B2 (en) Ligand for orphan nuclear receptor Nur77 and uses thereof
CN111566113B (zh) 大环化合物及其用途
BR112021004766A2 (pt) Composição para tratar doenças fibróticas, compreendendo composto de benzidril tioacetamida como ingrediente ativo
PT644878E (pt) Compostos 2,5-dio-2,5-di-hidro-1h-benzo¬b|azepina como antagonistas do receptor nmda
Xiao et al. Biologically active franchetine-type diterpenoid alkaloids: Isolation, synthesis, anti-inflammatory, agalgesic activities, and molecular docking
US8748598B2 (en) Analogs of 3-O-acetyl-11-keto-beta-boswellic acid
JP2021523934A (ja) ミトコンドリア脱共役剤として有用なアミノピラジンおよび関連化合物
CA2926928A1 (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
US11370766B2 (en) Sulfonyl amidine as indoleamine-2,3-dioxygenase inhibitor, and preparation method therefor and use thereof
Shim et al. Discovery of a NADPH oxidase inhibitor,(E)-3-cyclohexyl-5-(4-((2-hydroxyethyl)(methyl) amino) benzylidene)-1-methyl-2-thioxoimidazolidin-4-oneone, as a novel therapeutic for Parkinson's disease
WO2017076332A1 (zh) 具有acc1蛋白调控作用的五环三萜类化合物及其用途
WO2020077459A1 (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
CN106995368B (zh) 一种非atp竞争性fgfr1抑制剂及其应用
CN112996521B (zh) 用于诊断、治疗和预防赘生性和神经性障碍的组合物和方法
HK40001514A (en) Aminobenzoic acid derivatives for use as anti-inflammatory agents, anti-metastatic agents and/or anticancer agents
CN110117302B (zh) 神经退行性疾病的治疗药物及其应用
US9447063B2 (en) Disubstituted adamantyl derivative or pharmaceutically acceptable salt thereof, production method for same, and pharmaceutical composition for suppressing cancer metastasis comprising same as active ingredient
WO2019129909A1 (es) Benzopiranos prenilados agonistas de ppar
KR102322102B1 (ko) 염증성 질환의 예방, 개선 또는 치료용 조성물
RU2799454C2 (ru) Терапевтический препарат для лечения нейродегенеративных заболеваний и его применение
EP3753559A1 (en) Colitis improving agent

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190325

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20200408

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20200408

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20210318

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20210408

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20210708

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20211007

A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20220204

A045 Written measure of dismissal of application [lapsed due to lack of payment]

Free format text: JAPANESE INTERMEDIATE CODE: A045

Effective date: 20220623